natgillin/translations-raw huggingface dataset:
Tedizolid phosphate had no adverse effects on the fertility or reproductive performance of male rats, including spermatogenesis, at oral doses up to the maximum tested dose of 50 mg/kg/day, or adult female rats at oral doses up to the maximum tested dose of 15 mg/kg/day. 
Tedizolidfosfat nije imao štetnih učinaka na plodnost ili reproduktivnu sposobnost mužjaka štakora, uključujući spermatogenezu, pri peroralnim dozama do maksimalno testirane doze od 50 mg/kg/dan, ili odraslih ženki štakora pri peroralnim dozama do maksimalne testirane doze od 15 mg/kg/dan.
Peripheral neuropathy and optic nerve disorders 
Periferna neuropatija i poremećaji vidnog živca
These dose levels equate to exposure margins of ≥ 5.3-fold for males and ≥ 4.2-fold for females relative to tedizolid plasma AUC0-24 levels at the human oral therapeutic dose. 
Te su razine doze jednake granicama izloženosti ≥5,3 puta za mužjake i ≥4,2 puta za ženke u odnosu na razine tedizolida u plazmi AUC0-24 pri ljudskoj peroralnoj terapijskoj dozi.
Tedizolid inhibits mitochondrial protein synthesis. 
Tedizolid inhibira sintezu proteina u mitohondrijima.
CDAD must be considered in all patients who present with severe diarrhoea following antibiotic use. 
Na CDAD se mora posumnjati u svakog bolesnika u kojeg se javi teški proljev nakon primjene antibiotika.
In embryo-foetal studies, tedizolid phosphate was shown to produce foetal developmental toxicities in mice and rats. 
U embriofetalnim ispitivanjima, pokazalo se da tedizolidfosfat dovodi do fetalne razvojne toksičnosti u miševa i štakora.
The recommended dose is one 200 mg tablet once a day for 6 days. 
Preporučena doza je jedna tableta od 200 mg jedanput na dan tijekom 6 dana.
This effect is not clinically meaningful, and no dose adjustment for co-administered CYP3A4 substrates is necessary during tedizolid phosphate treatment. 
Ovaj učinak nije klinički značajan i nije potrebna prilagodba doze istodobno primijenjenih supstrata CYP3A4 tijekom liječenja tedizolidfosfatom.
Multiple sulfotransferase (SULT) enzymes (SULT1A1, SULT1A2, and SULT2A1) are involved in the biotransformation of tedizolid, to form an inactive and non-circulating sulphate conjugate found in the excreta. 
Više enzima sulfotransferaza (SULT) (SULT1A1, SULT1A2 i SULT2A1) uključeno je u biotransformaciju tedizolida i stvaranje neaktivnog i necirkulirajućeg sulfatnog konjugata koji se nalazi u ekskretima.
In an animal model of infection, the antibacterial activity of tedizolid was reduced in the absence of granulocytes. 
U životinjskom modelu infekcije, antibakterijska aktivnost tedizolida se smanjila u odsutnosti granulocita.
The time to tedizolid peak concentration with oral administration under fasting conditions is 6 hours faster than when administered with a high-fat, high-calorie meal (see section 5.2). 
Vrijeme do vršne koncentracije tedizolida kod peroralne primjene natašte je 6 sati brže nego kod primjene uz visokokalorični obrok koji sadrži visok postotak masnoća (vidjeti dio 5.2).
There is limited experience with tedizolid phosphate in the treatment of patients with concomitant acute bacterial skin and skin structure infections and secondary bacteremia and no experience in the treatment of ABSSSI with severe sepsis or septic shock. 
Iskustvo s tedizolidfosfatom u liječenju bolesnika s istodobnim akutnim bakterijskim infekcijama kože i kožnih struktura i sekundarne bakterijemije je ograničeno, a nema iskustva u liječenju akutnih bakterijskih infekcija kože i kožnih struktura s teškom sepsom ili septičkim šokom.
Spontaneous reports of serotonin syndrome associated with the co-administration of another member of the oxazolidinone class together with serotonergic agents have been reported (see section 4.5). 
Zabilježene su spontane prijave serotoninskog sindroma povezanog s istodobnom primjenom drugog lijeka iz skupine oksazolidinona uz serotonergičke lijekove (vidjeti dio 4.5).
Ask your doctor or pharmacist if you are not sure whether you are taking any of these medicines. 
Provjerite sa svojim liječnikom ili ljekarnikom ako niste sigurni uzimate li bilo koji od navedenih lijekova.
Safety was additionally evaluated in a randomized, double-blind, multicenter study conducted in China, the Philippines, Taiwan, and the US, which included a total 292 adult patients treated with tedizolid phosphate 200 mg administered IV and/or oral once daily for 6 days, and 297 patients treated with linezolid 600 mg administered IV and/or oral every 12 hours for 10 days for ABSSSI. 
Sigurnost je dodatno procijenjena u randomiziranom, dvostuko slijepom, multicentričnom ispitivanju provedenom u Kini, Filipinima, Tajvanu i Sjedinjenim Državama, a u kojem su zbog akutnih bakterijskih infekcija kože i kožnih struktura ukupno 292 odrasla bolesnika liječena tedizolidfosfatom u dozi od 200 mg primijenjenoj intravenski i/ili peroralno jedanput na dan tijekom 6 dana, a 297 bolesnika linezolidom u dozi od 600 mg primijenjenoj intravenski i/ili peroralno svakih 12 sati tijekom 10 dana.
• Dehydration 
• dehidracija
What Sivextro is and what it is used for What you need to know before you are given Sivextro How you will be given Sivextro Possible side effects 
Što je Sivextro i za što se koristi Što morate znati prije nego počnete dobivati Sivextro Kako ćete dobivati Sivextro Moguće nuspojave
The mean Cmax and AUC0-∞ for oral or IV administration of tedizolid phosphate 200 mg were similar in adolescent and in healthy adult subjects. 
Srednji Cmax i AUC0-∞ za peroralnu ili intravensku primjenu tedizolidfosfata od 200 mg bili su slični u adolescenata i u zdravih odraslih ispitanika.
The AUC/MIC ratio was the pharmacodynamic parameter shown to best correlate with efficacy in mouse thigh and lung S. aureus infection models. 
Omjer AUC/MIK pokazao se farmakodinamičkim parametrom koji je najbolje povezan s djelotvornošću u mišjim modelima infekcija bedra i pluća prouzročenih bakterijom S. aureus.
Infusion 
Infuzija
It is unknown whether tedizolid phosphate or its metabolites are excreted in human milk. 
Nije poznato izlučuju li se tedizolidfosfat ili njegovi metaboliti u majčino mlijeko.
Tedizolid is excreted in the breast milk of rats (see section 5.3). 
Tedizolid se izlučuje u mlijeko štakora tijekom laktacije (vidjeti dio 5.3).
Therefore, orally administered Sivextro can result in inhibition of BCRP at the intestinal level. 
Stoga, peroralno primijenjen lijek Sivextro može rezultirati inhibicijom BCRP-a na razini crijeva.
The following adverse reactions have been identified in two comparative pivotal Phase 3 studies with Sivextro (Table 1). 
Sljedeće su nuspojave zabilježene u dvama usporednim pivotalnim ispitivanjima faze 3 s lijekom Sivextro (Tablica 1).
Peripheral neuropathy, as well as optic neuropathy sometimes progressing to loss of vision, have been reported in patients treated with another member of the oxazolidinone class with treatment durations exceeding that recommended for tedizolid phosphate. 
Periferna neuropatija, kao i optička neuropatija koja ponekad može uznapredovati do gubitka vida, prijavljene su u bolesnika liječenih drugim lijekom iz skupine oksazolidinona kad je liječenje trajalo dulje od preporučenog razdoblja liječenja za tedizolidfosfat.
• Hot flush or blushing/redness in the face, neck or upper chest 
• navale vrućine ili crvenjenje/crvenilo na licu, vratu ili gornjem dijelu prsišta
• Fungal infections of skin, mouth and vagina (oral / vaginal thrush) 
• gljivične infekcije kože, usta i vagine (oralna/vaginalna kandidijaza)
Tedizolid phosphate is an oxazolidinone phosphate prodrug. 
Tedizolidfosfat je oksazolidinonski fosfatni predlijek.
The effects of tedizolid phosphate on fertility in humans have not been studied. 
Nisu ispitani učinci tedizolidfosfata na plodnost u ljudi.
The safety profile was similar when comparing patients receiving intravenous tedizolid phosphate alone to patients who received oral administration alone, except for a higher reported rate of gastrointestinal disorders associated with oral administration. 
Sigurnosni profil bio je sličan kada se usporede bolesnici koji su primali samo intravenski tedizolidfosfat s bolesnicima koji su primali lijek samo peroralno, osim za višu prijavljenu stopu poremećaja probavnog sustava povezanih s peroralnom primjenom.
Haemodialysis does not result in meaningful removal of tedizolid from systemic circulation, as assessed in subjects with end-stage renal disease (eGFR <15 mL/min). 
Hemodijaliza ne rezultira značajnim uklanjanjem tedizolida iz sistemske cirkulacije, kao što je procijenjeno u ispitanika u završnom stadiju bubrežne bolesti (eGFR <15 ml/min).
The reconstituted solution should be inspected visually for particulate matter prior to administration. 
Rekonstituiranu otopinu treba prije primjene vizualno pregledati na postojanje čestica.
• Abscess (swollen, pus-filled lump) 
• apsces (otečena, gnojna kvržica)
• Vaginal infection, inflammation or itching 
• vaginalna infekcija, upala ili svrbež
Insomnia Sleep disorder Anxiety Nightmare 
Psihijatrijski poremećaji nesanica poremećaji spavanja anksioznost noćne more
If you forget to take Sivextro 
Ako ste zaboravili uzeti Sivextro
• Decrease or loss of skin sensitivity, tingling/prickling skin sensation 
• smanjena osjetljivost kože ili gubitak osjetljivosti kože, trnci/osjećaj peckanja na koži
Sivextro must be reconstituted with water for injections and subsequently diluted in 250 mL of 0.9% sodium chloride for infusion. 
Sivextro se mora rekonstituirati s vodom za injekcije i zatim razrijediti u 250 ml 0,9%-tne otopine natrijevog klorida za infuziju.
Decreased platelets, decreased haemoglobin and decreased neutrophils have been observed in a few subjects during treatment with tedizolid phosphate. 
Smanjen broj trombocita, smanjena razina hemoglobina i smanjen broj neutrofila primijećeni su u nekoliko ispitanika tijekom liječenja tedizolidfosfatom.
What Sivextro looks like and contents of the pack Sivextro is an oval, yellow film-coated tablet imprinted with ‘TZD' on one side and ‘200' on the other side. 
Sivextro je ovalna, žuta filmom obložena tableta s utisnutom oznakom „TZD“ na jednoj strani i „200“ na drugoj strani.
In a 1-month immunotoxicology study in rats, repeated oral dosing of tedizolid phosphate was shown to significantly reduce splenic B cells and T cells and reduce plasma IgG titers. 
U jednomjesečnom ispitivanju imunotoksičnosti u štakora, ponovljeno peroralno doziranje tedizolidfosfata značajno je smanjilo B stanice i T stanice slezene i smanjilo je IgG titar u plazmi.
Mitochondrial dysfunction 
Poremećaj funkcije mitohondrija
Tedizolid did not alter activity of selected CYP isoenzymes, but induction of CYP3A4 mRNA was observed in vitro in hepatocytes. 
Tedizolid nije promijenio aktivnost tih izoenzima CYP, ali je zabilježena indukcija CYP3A4 mRNA in vitro u hepatocitima.
• Swelling in ankles and/or feet 
• oticanje gležnjeva i/ili stopala
There are no data from the use of tedizolid phosphate in pregnant women. 
Nema podataka o primjeni tedizolidfosfata u trudnica.
At steady state, tedizolid mean (SD) Cmax values of 2.2 (0.6) and 3.0 (0.7) mcg/mL and AUC values of 25.6 (8.5) and 29.2 (6.2) mcg·h/mL were similar with oral and IV administration of tedizolid phosphate, respectively. 
U stanju dinamičke ravnoteže, srednje vrijednosti (SD) Cmax od 2,2 (0,6) i 3,0 (0,7) μg/ml i vrijednosti AUC od 25,6 (8,5) i 29,2 (6,2) μg·h/ml tedizolida bile su slične kod peroralne, odnosno intravenske primjene tedizolidfosfata.
Do not take any medicine to treat your diarrhoea without first checking with your doctor. 
Nemojte uzimati lijekove protiv proljeva prije nego što se posavjetujete sa svojim liječnikom.
, Mg including Lactated Ringer's Injection and Hartmann's Solution. 
), uključujući otopinu za injekciju Ringerovog laktata i Hartmannovu otopinu.
No dose adjustment is necessary for co-administered CYP3A4 substrates during treatment with Sivextro. 
Nije potrebna prilagodba doze istodobno primijenjenih supstrata CYP3A4 tijekom liječenja lijekom Sivextro.
If in any doubt, contact your pharmacist for advice. 
Ako niste sigurni, obratite se ljekarniku za savjet.
Two placebo-controlled crossover studies were conducted to assess the potential of 200 mg oral tedizolid phosphate at steady state to enhance pressor responses to pseudoephedrine and tyramine in healthy individuals. 
Provedena su dva placebom kontrolirana ukrižena ispitivanja kako bi se procijenio potencijal 200 mg peroralnog tedizolidfosfata u stanju dinamičke ravnoteže za povećanje presorskog odgovora na pseudoefedrin i tiramin u zdravih osoba.
Following administration of a single 200 mg oral dose of tedizolid phosphate, the pharmacokinetics of tedizolid are not altered in patients with moderate (n=8) or severe (n=8) hepatic impairment (Child-Pugh Class B and C). 
Nakon primjene jednokratne peroralne doze tedizolidfosfata od 200 mg, farmakokinetika tedizolida nije se promijenila u bolesnika s umjerenim (n=8) ili teškim (n=8) oštećenjem funkcije jetre (Child-Pugh stadij B i C).
• loss of sensitivity in your hands or feet (such as numbness, prickling/tingling, or sharp pains) 
• gubitak osjetljivosti u šakama ili stopalima (primjerice utrnulost, peckanje/trnci ili oštri bolovi)
Table 1 Frequency of adverse reactions by System Organ Class in comparative clinical studies 
Tablica 1 Učestalost nuspojava prema klasifikaciji organskih sustava u usporednim kliničkim ispitivanjima
Neuropathy (optic and peripheral) has not been reported in patients treated with tedizolid phosphate at the recommended treatment duration of 6 days. 
Neuropatija (optička i periferna) nije zabilježena u bolesnika liječenih tedizolidfosfatom tijekom preporučenog trajanja liječenja od 6 dana.
Tedizolid phosphate is converted by endogenous plasma and tissue phosphatases to the microbiologically active moiety, tedizolid. 
Tedizolidfosfat se pretvara endogenim fosfatazama plazme i tkiva u mikrobiološki aktivni spoj, tedizolid.
Reconstitute the contents of the vial with 4 mL water for injections, and swirl gently until the powder has dissolved entirely. 
Rekonstituirajte sadržaj bočice sa 4 ml vode za injekcije i lagano okrećite dok se prašak potpuno ne otopi.
• Respiratory tract (sinuses, throat and chest) infection 
• infekcija dišnih puteva (sinusi, grlo i prsište)
There is no Phase 3 clinical experience in patients with co-administration of tedizolid phosphate with serotonergic agents such as selective serotonin re-uptake inhibitors [SSRI], serotonin norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants, MAO inhibitors, triptans, and other medicines with potential adrenergic or serotonergic activity. 
Nema iskustva iz kliničkih ispitivanja faze 3 u bolesnika s istodobnom primjenom tedizolidfosfata uz serotonergičke lijekove kao što su selektivni inhibitori ponovne pohrane serotonina [engl. selective serotonin re-uptake inhibitors, SSRI], inhibitori ponovne pohrane serotonina i noradrenalina (engl. serotonin norepinephrine reuptake inhibitors, SNRI), triciklički antidepresivi, inhibitori MAO, triptani i drugi lijekovi s potencijalnom adrenergičkom ili serotonergičkom aktivnošću.
In a mouse thigh infection model of S. aureus, the antibacterial activity of tedizolid was reduced in the absence of granulocytes. 
U mišjem modelu infekcije bedra prouzročene bakterijom S. aureus, antibakterijska aktivnost tedizolida bila je smanjena u odsutnosti granulocita.
• sulfasalazine (used to treat inflammatory bowel diseases) 
• sulfasalazin (koristi se za liječenje upalnih bolesti crijeva)
If possible, an interruption of the coadministered BCRP substrate medicinal product (such as imatinib, lapatinib, methotrexate, pitavastatin, rosuvastatin, sulfasalazine, and topotecan) should be considered during the 6 days of treatment with oral tedizolid phosphate. 
Ako je moguće, potrebno je razmotriti prekid istodobne primjene lijeka koji je supstrat BCRP-a (kao što je imatinib, lapatinib, metotreksat, pitavastatin, rosuvastatin, sulfasalazin i topotekan) tijekom 6 dana liječenja peroralnom primjenom tedizolidfosfata.
Clostridioides difficile associated diarrhoea 
Proljev povezan s Clostridioides difficile
What Sivextro is and what it is used for What you need to know before you take Sivextro How to take Sivextro 
Što je Sivextro i za što se koristi Što morate znati prije nego počnete uzimati Sivextro Kako uzimati Sivextro
• if you are allergic to tedizolid phosphate or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Sivextro: • ako ste alergični na tedizolidfosfat ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
The contents of the vial should be reconstituted with 4 mL of water for injections, and be swirled gently until the powder has dissolved entirely. 
Sadržaj bočice mora se rekonstituirati sa 4 ml vode za injekcije i lagano okretati dok se prašak potpuno ne otopi.
Sivextro is an antibiotic that contains the active substance tedizolid phosphate. 
Sivextro je antibiotik koji sadrži djelatnu tvar tedizolidfosfat.
Do not use this medicine after the expiry date which is stated on the vial label after “EXP”. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na bočici iza oznake „EXP“.
The safety and efficacy of tedizolid phosphate when administered for periods longer than 6 days have not been established. 
Sigurnost i djelotvornost tedizolidfosfata kada se primjenjuje duže od 6 dana nisu ustanovljene.
• Dry mouth, constipation, indigestion, pain/discomfort in the belly (abdomen), retching, dry heaving, bright red blood in the stool 
• suha usta, zatvor, probavne tegobe, bol/nelagoda u trbuhu (abdomenu), dizanje želuca, svijetlo crvena krv u stolici
Clostridioides difficile associated diarrhoea (CDAD) has been reported for tedizolid phosphate (see section 4.8). 
Clostridioides difficile associated diarrhoea, CDAD) (vidjeti dio 4.8).
• Sleepiness, abnormal sleep pattern, difficulty sleeping, nightmares (unpleasant/disturbing dreams) 
• pospanost, poremećen obrazac spavanja, poteškoće sa spavanjem, noćne more
Blood and lymphatic system disorders 
Poremećaji krvi i limfnog sustava limfadenopatija
In Phase 3 studies, subjects taking serotonergic agents including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and serotonin 5-hydroxytryptamine (5-HT1) receptor agonists (triptans), meperidine, or buspirone were excluded. 
U ispitivanjima faze 3 isključeni su ispitanici koji uzimaju serotonergičke lijekove uključujući antidepresive, primjerice selektivne inhibitore ponovne pohrane serotonina (engl. selective serotonin reuptake inhibitors, SSRI), tricikličke antidepresive i agoniste receptora serotonina 5-hidroksitriptamina (5-HT1) (triptane), meperidin ili buspiron.
• Swollen or enlarged lymph nodes 
• otečeni ili povećani limfni čvorovi
Following administration of a single 200 mg IV dose of tedizolid phosphate to 8 subjects with severe renal impairment defined as eGFR <30 mL/min, the Cmax was basically unchanged and AUC0-∞ was changed by less than 10% compared to 8 matched healthy subject controls. 
Nakon primjene jednokratne intravenske doze tedizolidfosfata od 200 mg u 8 ispitanika s teškim oštećenjem funkcije bubrega definiranim kao eGFR <30 ml/min, Cmax je bio u načelu neizmijenjen, a AUC0-∞ je bio izmijenjen za manje od 10% u usporedbi s 8 odgovarajućih zdravih kontrolnih ispitanika.
Lactic acidosis has not been reported in patients treated with tedizolid phosphate at the recommended treatment duration of 6 days. 
Laktacidoza nije zabilježena u bolesnika liječenih tedizolidfosfatom tijekom preporučenog trajanja liječenja od 6 dana.
These effects occurred at plasma tedizolid exposure levels (AUC) ≥3-fold greater than the expected human plasma exposure associated with the therapeutic dose. 
Ti su se učinci javili pri razinama izloženosti tedizolidu u plazmi (AUC) ≥3 puta većim od očekivane izloženosti u ljudskoj plazmi povezanoj s terapijskom dozom.
Oral and intravenous tedizolid phosphate is a prodrug that is rapidly converted by phosphatases to tedizolid, the microbiologically active moiety. 
Peroralni i intravenski tedizolidfosfat je predlijek koji fosfataze brzo pretvaraju u tedizolid, mikrobiološki aktivni spoj.
The mean steady state volume of distribution of tedizolid in healthy adults (n=8) following a single intravenous dose of tedizolid phosphate 200 mg ranged from 67 to 80 L. 
Srednji volumen distribucije tedizolida u stanju dinamičke ravnoteže u zdravih odraslih osoba (n=8) nakon jedne intravenske doze tedizolidfosfata od 200 mg varirao je od 67 do 80 l.
EU/1/15/991/002 1 vial EU/1/15/991/003 6 vials 
EU/1/15/991/002 1 bočica EU/1/15/991/003 6 bočica
These effects showed evidence of reversibility and occurred at plasma tedizolid exposure levels (AUC) ≥6-fold greater than the plasma exposure associated with the human therapeutic dose. 
Ti su se učinci pokazali reverzibilnima i javili su se pri razinama izloženosti tedizolidu u plazmi (AUC) ≥6 puta većim od izloženosti u plazmi povezanoj s ljudskom terapijskom dozom.
Table 1 Frequency of adverse reactions by System Organ Class in pooled Phase 3 comparative clinical studies 
Tablica 1 Učestalost nuspojava prema klasifikaciji organskih sustava u udruženim usporednim kliničkim ispitivanjima faze 3
The following adverse reactions have been identified in two comparative pivotal Phase 3 studies and one post-authorisation study with Sivextro (Table 1). 
Sljedeće su nuspojave zabilježene u dvama usporednim pivotalnim ispitivanjima faze 3 i jednom ispitivanju nakon dobivanja odobrenja za stavljanje lijeka u promet s lijekom Sivextro (Tablica 1).
It must be administered as an intravenous infusion only. 
Smije se primjenjivati isključivo intravenskom infuzijom.
Foetal developmental effects occurring in mice in the absence of maternal toxicity included reduced foetal weights and an increased incidence of costal cartilage fusion (an exacerbation of the normal genetic predisposition to sternal variations in the CD-1 strain of mice) at the high dose of 25 mg/kg/day (4-fold the estimated human exposure level based on AUCs). 
Učinci na fetalni razvoj koji se pojavljuju u miševa u odsustvu toksičnosti za majku uključivali su smanjenu fetalnu težinu i povećanu incidenciju fuzije rebrene hrskavice (pogoršanje normalne genetske predispozicije za sternalne promjene u mišjem soju CD-1) pri visokoj dozi od 25 mg/kg/dan (4 puta viša od procijenjene ljudske razine izloženosti na temelju AUC-a).
The reconstituted solution will be withdrawn from the vial and added to an infusion bag of 0.9% sodium chloride in the hospital. 
Rekonstituiranu otopinu treba izvući iz bočice i dodati u infuzijsku vrećicu 0,9%-tne otopine natrijevog klorida u bolnici.
Tedizolid was positive in an in vitro CHL cell chromosomal aberration assay, but negative for genotoxicity in other in vitro assays (Ames, mouse lymphoma mutagenicity) and in vivo in a mouse bone marrow micronucleus assay. 
Tedizolid je bio pozitivan u in vitro testu kromosomske aberacije u stanicama CHL, ali je bio negativan na genotoksičnost u drugim in vitro testovima (Ames, mutagenost mišjeg limfoma) i in vivo u mikronukleusnom testu na mišjoj koštanoj srži.
The reconstituted solution must be administered as an intravenous infusion only. 
Rekonstituirana otopina smije se primjenjivati isključivo intravenskom infuzijom.
It is available in 6 × 1 tablets in perforated unit-dose blisters. 
Lijek je dostupan u perforiranim blisterima s jediničnim dozama sa 6 × 1 tableta.
It is not known if Sivextro passes into breast milk in humans. 
Nije poznato izlučuje li se Sivextro u majčino mlijeko.
Contact your doctor, pharmacist or nearest hospital casualty department as soon as possible if you have taken more tablets than you should, and take your medicine with you. 
Ako uzmete više lijeka Sivextro nego što ste trebali Obratite se čim prije liječniku, ljekarniku ili hitnoj službi najbliže bolnice ako ste uzeli više tableta nego što ste trebali, i ponesite lijek sa sobom.